Match!
Milena Music
University of Toronto
1Publications
Publications 1
Newest
Published on Dec 1, 2019in Clinical Proteomics2.89
Milena Music (U of T: University of Toronto), Antoninus Soosaipillai35
Estimated H-index: 35
(MSH: Mount Sinai Hospital, Toronto)
+ 3 AuthorsEleftherios P. Diamandis97
Estimated H-index: 97
Background Autoantibodies are produced when tolerance to self-antigens is broken and they can be mediators of tissue injury and systemic inflammation. They are excellent biomarkers because they are minimally invasive to screen and are highly abundant in serum due to limited proteolysis and slow clearance. Conventionally used methods of identifying autoantibodies in patient sera include indirect immunofluorescence, enzyme-linked immunoabsorbent assays (ELISAs) and protein microarrays. Here we pre...
Milena Music (U of T: University of Toronto), Marco Adelmo James Iafolla1
Estimated H-index: 1
(Princess Margaret Cancer Centre)
+ -3 AuthorsEleftherios P. Diamandis97
Estimated H-index: 97
(Mount Sinai Hospital)
Immune checkpoint blockade (ICB) employs antibody-targeting of specific inhibitory receptors and ligands. The major limitations of ICB, such as high cost, limited success rate and immune-related adverse events (irAEs), highlight the need for predictive biomarkers. We analyzed pre- and post-immunotherapy serum samples of 24 patients treated with pembrolizumab for changes in PD-1 and over 1,000 additional protein markers using a multiplex proximity extension assay (PEA) to identify potential predi...
Published on Oct 3, 2018in Critical Reviews in Clinical Laboratory Sciences4.82
Milena Music (U of T: University of Toronto), Ioannis Prassas13
Estimated H-index: 13
(MSH: Mount Sinai Hospital, Toronto),
Eleftherios P. Diamandis97
Estimated H-index: 97
AbstractCancer immunotherapy, a treatment that selectively augments a patient’s anti-tumor immune response, is a breakthrough advancement in personalized medicine. A subset of cancer patients undergoing immunotherapy have displayed robust and long-lasting therapeutic responses. Currently, the spotlight is on the use of blocking antibodies against the T-cell checkpoint molecules, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programed cell death-1 (PD-1)/programed death-ligand 1 (PD-L1...
1